Navigation Links
Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
Date:5/7/2009

EAST BRUNSWICK, N.J., May 7 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its biologics license application (BLA) for KRYSTEXXA(TM) (pegloticase), a novel biological drug for treatment failure gout (TFG) patients, will be reviewed by the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) on June 16, 2009.

In December, the FDA accepted the Company's BLA for KRYSTEXXA and granted priority review status, which is a designation assigned to drugs that are deemed by the FDA to have the potential to provide an important advancement in treatment or provide a treatment for a disease or condition for which there is no adequate therapy available.

In January, the Company submitted to the FDA several key amendments for the KRYSTEXXA BLA to further strengthen and clarify the overall BLA application. The FDA reviewed and accepted the amendments and determined that the additional information contained in the submissions constituted major amendments. In an effort to include the amendments as part of the review, the FDA elected to extend the BLA review period and assigned a revised PDUFA date of August 1, 2009.

ABOUT KRYSTEXXA(TM)

KRYSTEXXA(TM) (pegloticase) is a pegylated recombinant mammalian urate oxidase in development to control hyperuricemia and its clinical consequences in patients for whom conventional therapy is contraindicated or has been ineffective. The two Phase 3 pivotal trials assessed the safety and efficacy of a six-month course of pegloticase therapy in patients with treatment failure gout, under the auspices of an SPA from the FDA. KRYSTEXXA was granted orphan drug indication by the FDA in 2001. Savient's KRYSTEXXA BLA filing includes data from both the six-month placebo-controlled Phase 3 piv
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
3. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
4. Savient Announces Appointment of David Gionco as Chief Financial Officer
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
7. Savient Submits Biologics License Application (BLA) for pegloticase
8. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
9. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
10. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
11. GeoVax Labs, Inc. Announces First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... Yan, Distinguished Professor of Engineering at the University ... to solve problems in energy engineering, environmental sustainability ... on zeolites, porous rock with a well-defined, crystalline ... is so precisely decided that zeolites can separate ... of an angstrom (one-tenth of a nanometer), making ...
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... Sept. 14 Helix BioPharma Corp. (TSX, FSE: "HBP" / ... list its shares of common stock on the NYSE Amex ... stock will begin trading on the NYSE Amex on September ... delist from the OTCQX once trading begins on the NYSE ...
... 14 The launch of IntriMed Technologies and ... in Oxnard, Calif. were announced today by IntriPlex ... manufacture of ultra-precise components for the data storage ... heritage of engineering innovation, IntriMed ( www.intrimed.com ) ...
... HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Biology Technology:Helix BioPharma Approved for NYSE Amex Listing 2Helix BioPharma Approved for NYSE Amex Listing 3IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 2IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 2Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 4Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 5Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 6Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 7Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 8
(Date:7/24/2014)... RIVERSIDE, Calif. -- To reduce fire hazard in the ... of mechanically cutting woody shrubs and suppressed trees (ladder ... then burned during periods of low fire danger in ... burning and minimize hazardous air pollutants, managers often cover ... polyethylene plastic, commonly referred to as agricultural plastic, in ...
(Date:7/24/2014)... study funded by the New Jersey Recovery Fund and ... of Planning and Public Policy at Rutgers University has ... skeptical about the likelihood of community-based rebuilding solutions. Of ... indicated they were "pessimistic" or "very pessimistic" that the ... be rebuilt better than they were before the storm; ...
(Date:7/24/2014)... which life arose have been maintained in our cells today ... Research published today in the Journal of Biological Chemistry ... also in animals still perform ancient reactions thought to have ... billion years ago. , The primordial soup theory suggests that ... of the combination of metals, gases from the atmosphere and ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... It just got easier to pinpoint biological hot spots in ... a pinpoint. Microscopic algae are called phytoplankton and range from ... being 1/100th the size of a human hair. But as ... of Vancouver Island, British Columbia, are big players when it ...
... MD FASEB MARC (Minority Access to Research Careers) ... American Society for Bone & Mineral Research (ASBMR) 2010 ... 2010. These awards are meant to promote the ... the mainstream of the basic science community and to ...
... October 6, 2010 - A first-of-its-kind study that tracked the ... tagged in the Hudson River discovered that these fish move ... south as Georgia and as far north as Nova Scotia, ... will need to address long-range oceanic threats to the species ...
Cached Biology News:UW-built device reveals invisible world teeming with microscopic algae 2Study provides data that can inform Atlantic sturgeon recovery efforts 2Study provides data that can inform Atlantic sturgeon recovery efforts 3
...
... receptors constitute the principal excitatory ... classes of glutamate receptors exist: ... Ionotropic glutamate receptors are oligomeric ... NMDA1-3, KAI-2) which comprise ligand-gated ...
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
Recommended fro Western blotting application...
Biology Products: